{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:22:42Z","timestamp":1790140962432,"version":"4.0.1"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170547, 81873558"],"award-info":[{"award-number":["82170547, 81873558"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>PD-1 inhibitors, as one of commonly used immune checkpoint inhibitors, enable T-cell activation and prevent immune escape by blocking the PD-1\/PD-L1 signaling pathway. They have transformed the treatment landscape for cancer in recent years, due to the advantages of significantly prolonging patients\u2019 survival and improving their life quality. However, the ensuing unpredictable immune-related adverse effects (irAEs) plague clinicians, such as colitis and even potentially fatal events like intestinal perforation and obstruction. Therefore, understanding the clinical manifestations and grading criteria, underlying mechanisms, available diverse therapies, accessible biomarkers, and basis for risk stratification is of great importance for the management. Current evidence suggests that irAEs may be a marker of clinical benefit to immunotherapy in patients, so whether to discontinue PD-1 inhibitors after the onset of irAEs and rechallenge after remission of irAEs requires further evaluation of potential risk-reward ratios as well as more data from large-scale prospective studies to fully validate. At the end, the rare gastrointestinal toxicity events caused by PD-1 inhibitors are also sorted out. This review provides a summary of available data on the gastrointestinal toxicity profile caused by PD-1 inhibitors, with the aim of raising clinicians\u2019 awareness in daily practice, so that patients can safely benefit from therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1190850","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T02:39:16Z","timestamp":1687142356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management"],"prefix":"10.3389","volume":"14","author":[{"given":"Yiyu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangmei","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangru","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13045-021-01213-z","article-title":"Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019","volume":"14","author":"Lin","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05707-3","article-title":"Multinational association of supportive care in cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors","volume":"28","author":"Dougan","year":"2020","journal-title":"Support Care Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Targeted Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflammation Bowel Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2021.00039","article-title":"Gastrointestinal disorders as immune-related adverse events","volume":"2","author":"Balducci","year":"2021","journal-title":"Explor Targeted Anti-tumor Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z","article-title":"T Cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.12703\/r\/10-30","article-title":"Recent advances in understanding the Th1\/Th2 effector choice","volume":"10","author":"Butcher","year":"2021","journal-title":"Fac Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000749","article-title":"T-Bet and eomesodermin are required for T cell-mediated antitumor immune responses","volume":"185","author":"Zhu","year":"2010","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1186\/s12885-019-6138-7","article-title":"Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports","volume":"19","author":"Yoshino","year":"2019","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0362","article-title":"Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1\/Tc1 cytokines","volume":"10","author":"Reschke","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158017","article-title":"Distinct immune signatures indicative of treatment response and immune-related adverse events in melanoma patients under immune checkpoint inhibitor therapy","volume":"22","author":"Reschke","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108377","article-title":"Immune-related adverse events of checkpoint inhibitors: insights into immunological dysregulation","volume":"22","author":"Yang","year":"2020","journal-title":"Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40425-018-0399-6","article-title":"Resident memory T cells, critical components in tumor immunology","author":"Mami-Chouaib","year":"2018","journal-title":"J Immunotherapy Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1540-2","article-title":"ILC3 function as a double-edged sword in inflammatory bowel diseases","volume":"10","author":"Zeng","year":"2019","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.isci.2018.10.021","article-title":"Immunogenomic landscape contributes to hyperprogressive disease after anti-PD-1 immunotherapy for cancer","volume":"9","author":"Xiong","year":"2018","journal-title":"Iscience"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01235","article-title":"Probiotics lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.07.029","article-title":"Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer","volume":"184","author":"Goc","year":"2021","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622442","article-title":"B cells in patients with melanoma: implications for treatment with checkpoint inhibitor antibodies","volume":"11","author":"Willsmore","year":"2020","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798","article-title":"Early b cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205378119","article-title":"Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events","volume":"119","author":"Tsukamoto","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J Transl Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CJI.0000000000000255","article-title":"Immunoglobulin G and subclasses as potential biomarkers in metastatic melanoma patients starting checkpoint inhibitor treatment","volume":"42","author":"Diem","year":"2019","journal-title":"J Immunother"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.10011","article-title":"Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma","volume":"38","author":"Hassel","year":"2020","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-Based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952546","article-title":"Global research trends on the links between gut microbiota and cancer immunotherapy: a bibliometric analysis (2012-2021)","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01965-2","article-title":"Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome","author":"Simpson","year":"2022","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1099063","article-title":"Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdz224","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"30","author":"Chaput","year":"2019","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0196","article-title":"The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer","volume":"8","author":"Hakozaki","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921223117","article-title":"Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade","volume":"117","author":"Sun","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20200520-01598","article-title":"[Protective effect and mechanism of lactobacillus rhamnosus on immune checkpoint inhibitors related colitis in mice]","volume":"100","author":"Tan","year":"2020","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/gastro\/goz065","article-title":"Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy","volume":"8","author":"Rajha","year":"2020","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202000426","article-title":"Functional roles of b-vitamins in the gut and gut microbiome","volume":"64","author":"Uebanso","year":"2020","journal-title":"Mol Nutr Food Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1917597117","article-title":"Microbiota-derived butyrate dynamically regulates intestinal homeostasis through regulation of actin-associated protein synaptopodin","volume":"117","author":"Wang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00253","article-title":"Propionate ameliorates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress","volume":"7","author":"Tong","year":"2016","journal-title":"Front Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-1014","article-title":"The gut microbiome is associated with clinical response to anti-PD-1\/PD-L1 immunotherapy in gastrointestinal cancer","volume":"8","author":"Peng","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15691","article-title":"Flexible sigmoidoscopy may be sufficient for initial evaluation of suspected immunotherapy-mediated colitis: a cross-sectional study","volume":"37","author":"De Silva","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3892\/mco.2021.2227","article-title":"Efficacy and safety of infliximab for steroid-resistant immune-related adverse events: a retrospective study","volume":"14","author":"Kadokawa","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0155","article-title":"Etanercept for the treatment of rheumatoid arthritis","volume":"10","author":"Zhao","year":"2018","journal-title":"Immunotherapy"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J For Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update (vol 39, pg 4073, 2021)","volume":"40","author":"Schneider","year":"2022","journal-title":"J OF Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B66","doi-asserted-by":"publisher","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with still's disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2019.03.002","article-title":"Efficacy of tofacitinib treatment in ulcerative colitis","volume":"42","author":"Panes","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2002527","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani","year":"2020","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.609705","article-title":"Research status and molecular mechanism of the traditional Chinese medicine and antitumor therapy combined strategy based on tumor microenvironment","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.03.004","article-title":"Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B74","doi-asserted-by":"publisher","first-page":"105444","DOI":"10.1016\/j.phrs.2021.105444","article-title":"Baicalin and the liver-gut system: pharmacological bases explaining its therapeutic effects","volume":"165","author":"Hu","year":"2021","journal-title":"Pharmacol Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154446","article-title":"Brucea javanica oil emulsion significantly improved the effect of anti-programmed cell death protein-1 immunotherapy","volume":"107","author":"Meng","year":"2022","journal-title":"Phytomedicine"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1638-6","article-title":"Gegen qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment","volume":"10","author":"Lv","year":"2019","journal-title":"Cell Death Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.08.002","article-title":"Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer","volume":"86","author":"Yin","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2023.02.007","article-title":"Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction","volume":"91","author":"Li","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.749064","article-title":"Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis","volume":"11","author":"Bastacky","year":"2021","journal-title":"Front Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937476","article-title":"Vitamin d metabolism pathway polymorphisms are associated with efficacy and safety in patients under anti-PD-1 inhibitor therapy","volume":"13","author":"Luo","year":"2022","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-020-01274-7","article-title":"The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Jin","year":"2020","journal-title":"Mol Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906824","article-title":"Increased circulating levels of CRP and IL-6 and decreased frequencies of T and b lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer","volume":"12","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174167","article-title":"Extracellular vesicle-derived protein file from peripheral blood predicts immune-related adverse events in gastric cancer patients receiving immunotherapy","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers"},{"key":"B87","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/apt.15485","article-title":"Review article: the genetics of the human leucocyte antigen region in inflammatory bowel disease","volume":"50","author":"Ashton","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25143219","article-title":"Vitamin d signaling in inflammation and cancer: molecular mechanisms and therapeutic implications","volume":"25","author":"El-Sharkawy","year":"2020","journal-title":"Molecules"},{"key":"B89","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-019-0967-5","article-title":"The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy","volume":"18","author":"Huang","year":"2019","journal-title":"Mol Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1693540","article-title":"Role of inducible Co-stimulator (ICOS) in cancer immunotherapy","volume":"20","author":"Amatore","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.immuni.2021.11.017","article-title":"Engagement of the costimulatory molecule ICOS in tissues promotes establishment of CD8(+) tissue-resident memory T cells","volume":"55","author":"Peng","year":"2022","journal-title":"Immunity"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.12.012","article-title":"Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients","volume":"108","author":"Ben-Betzalel","year":"2019","journal-title":"Eur J Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5577-5","article-title":"Case report: reinitiating pembrolizumab treatment after small bowel perforation","volume":"19","author":"Beck","year":"2019","journal-title":"BMC Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-020-01261-x","article-title":"Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis","volume":"14","author":"Kayashima","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07142-3","article-title":"Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody","volume":"20","author":"Matsuoka","year":"2020","journal-title":"BMC Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic Rev meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors-a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B100","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00790-w","article-title":"Association between immune-related adverse events and the prognosis of patients with advanced gastric cancer treated with nivolumab","volume":"16","author":"Kono","year":"2021","journal-title":"Targeted Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13149","article-title":"Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"10","author":"Komiya","year":"2019","journal-title":"Thorac Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03045-9","article-title":"Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1\/PD-L1 checkpoint inhibitors leading to treatment discontinuation","volume":"71","author":"Russano","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade >= 2 immune-related adverse events in patients with cancer (vol 8, e001622, 2020)","volume":"9","author":"Allouchery","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3393\/ac.2020.00213.0030","article-title":"Colonic perforation after treatment with nivolumab in esophageal cancer: a case report","volume":"37","author":"Cho","year":"2021","journal-title":"Ann Coloproctol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"3406437","DOI":"10.1155\/2018\/3406437","article-title":"Anti-PD-1 therapy-associated perforating colitis","volume":"2018","author":"Celli","year":"2018","journal-title":"Case Rep Gastrointest Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-2501","article-title":"Immune checkpoint inhibitor-induced colitis complicated with inflammatory intestinal obstruction: a case report and literature review","author":"Tan","year":"2022","journal-title":"Trans Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0694-x","article-title":"A case of checkpoint inhibitor-induced celiac disease","volume":"7","author":"Alsaadi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000958","article-title":"Immune checkpoint inhibitor-associated celiac disease","volume":"8","author":"Badran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.871452","article-title":"Case report: fulminant celiac disease with combination immune checkpoint therapy","volume":"13","author":"Falade","year":"2022","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04367-6","article-title":"Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients","author":"Mathew","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s40425-019-0714-x","article-title":"Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1190850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T02:39:20Z","timestamp":1687142360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1190850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":117,"alternative-id":["10.3389\/fimmu.2023.1190850"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1190850","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"article-number":"1190850"}}